Baltimore-based Pharos secures Zika vaccine tech

zika

The race to advance a Zika vaccine will have a new entrant in Baltimore-based Pharos Biologicals. The development-stage company this week announced it has been awarded technology for influenza and flavivirus vaccines from the Johns Hopkins University School of Medicine.

The patented Lysosome-Associated Membrane Protein DNA vaccine technology, the company says, features a rapid development timeline, is highly stable and directly delivers antigens to cell proteins to prompt immune responses. Invented by Johns Hopkins professor and Pharos founder Dr. J. Thomas August, the vaccines utilize normal cellular mechanisms to bolster vaccine immune responses and do not contain live virus, the company’s statement said.

Pharos anticipates it will be able to start Phase I testing with the platform in Zika this fall. Back in February, Plymouth Meeting, PA-based Inovio said it’s shooting to start a Phase I Zika vaccine trial on the same timeline while the U.S. National Institutes of Health that month said it’s looking to start Phase I testing this summer.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Pharos joins a Zika vaccine R&D scramble that features more than 18 companies and organizations as the virus has raced around the globe to more 50 countries and territories, according to WHO figures. Founded in 2015, the Baltimore-based company also has aspirations in dengue and influenza. David Wise, an executive in the med-tech startup and venture capital community in Baltimore, serves as CEO.

In October 2015, the LAMP vaccine tech showed commercial promise when Immunomic Therapeutics sold a license for allergen vaccines to Japan’s Astellas for $300 million; Johns Hopkins previously awarded that license.

- here’s the release

Related Article:
Health agencies inform on Zika vaccine timeline

An image predicting the spread of Zika, courtesy of eLifeSciences.org.

Read more on

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.